Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients
Launched by NURHASAN AGUNG PRABOWO · Jun 1, 2022
Trial Information
Current as of May 12, 2025
Unknown status
Keywords
ClinConnect Summary
This cross-sectional study involves 11 dengue fever patients, consisting of 9 men and two women, at Sebelas Maret University Hospital (RS UNS), Sukoharjo. The study was conducted in May 2021. Inclusion criteria included patients who were hospitalised at UNS Hospital with the following criteria: (1) adult patients (19-65 years); (2) diagnosed with dengue hemorrhagic fever according to WHO 2011 criteria; (3) routine blood examination at least once in seven days since the onset of fever; and (4) checked alanine transaminase and aspartate transaminase levels at least once in seven days from the...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients who were hospitalized at UNS Hospital with the following criteria: (1) adult patients (19-65 years); (2) diagnosed with dengue hemorrhagic fever according to WHO 2011 criteria; (3) routine blood examination at least once in seven days since the onset of fever; and (4) checked alanine transaminase and aspartate transaminase levels at least once in seven days from the onset of fever.
- Exclusion Criteria:
- • -
About Nurhasan Agung Prabowo
Nurhasan Agung Prabowo is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes. With a strong commitment to ethical standards and regulatory compliance, he leads initiatives that explore innovative therapies and treatment modalities. His expertise encompasses the design, implementation, and management of clinical trials across diverse therapeutic areas. By fostering collaboration with healthcare professionals, research institutions, and regulatory bodies, Nurhasan aims to contribute significantly to the body of medical knowledge and enhance the efficacy of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sukoharjo, Central Java, Indonesia
Sukoharjo, Central Java, Indonesia
Patients applied
Trial Officials
Nurhasan Agung Prabowo, MD
Principal Investigator
Universitas Sebelas Maret
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials